Celosia Therapeutics · Undisclosed · Phase 1b Finanzierung
Australian biotech Celosia Therapeutics announced the first patient dosed in its Phase 1b clinical trial of CTx1000 for Amyotrophic Lateral Sclerosis (ALS). The company is developing gene therapies for neurodegenerative diseases. While not an explicit venture round, this clinical milestone represents significant progress in the company's development and future funding prospects.
Source Brief
Australian biotech Celosia Therapeutics announced the first patient dosed in its Phase 1b clinical trial of CTx1000 for Amyotrophic Lateral Sclerosis (ALS). The company is developing gene therapies for neurodegenerative diseases. While not an explicit venture round, this clinical milestone represents significant progress in the company's development and future funding prospects.